Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.

"Conflict-of-interest disclosure: O.C. reports honoraria for consulting from Bristol Myers Squibb (BMS) and research funding from Jazz Pharmaceuticals. M.H. reports consulting and/or other fees from Adaptive Biotechnologies, Amgen, Aptitude Health, Blueprint Oncology, Celgene, Decibio, Diaceutics, Guidepoint, Seattle Genetics, Stemline, Tegus, Janssen, and BMS. C.T. is a current equity holder in private company, AbbVie. A.K. reports consulting and/or other fees from AbbVie, Blueprint Medicines, Celgene, Constellation, CTI Biopharma, Incyte, Novartis, Prelude, Protagonist, and Sierra Oncology; and grant funding from BMS, Constellation, Novartis, Prelude, Protagonist, and Sierra Oncology. E.P. reports consulting and/or other fees from Blueprint Medicines, Novartis, and Taiho Oncology. G.R. reports consulting and/or other fees from Actinium, AbbVie, Agios, Amgen, Astellas, AstraZeneca, BMS, Blueprint Medicines, bluebird bio, GlaxoSmithKline, Janssen, Jasper, Jazz, MEI Pharma, Mesoblast, Novartis, Pfizer, Syndax, and Takeda. P.D. reports consulting and/or other fees from Janssen, Servier, AbbVie, and BMS. D.S. reports consulting and/or other fees from Aprea Therapeutics, Avencell Europe GmbH, bluebird bio, BMS, Gilead Sciences, Incyte, Intellia Therapeutics, Janssen Global Services, Jazz Pharmaceuticals, Kite Pharma, Molecular Partners AG, Novartis, Servier Pharmaceuticals, Shattuck Labs, Syndax Pharmaceuticals, Syros Pharmaceuticals, and Takeda Pharmaceutical. K.S. reports consulting and/or other fees from Arog, Astellas Pharma, BerGenBio, BMS, Curis, Gilead Sciences, Mablytics, Novartis, Pfizer Pharmaceuticals, and Incyte. R.K. reports consulting and/or other fees from AbbVie, Acceleron Pharma, Agios Pharmaceuticals, Alexion Pharmaceuticals, BMS, Celgene, CTI Biopharma, Daiichi Sankyo, Geron, Janssen Biotech, Jazz Pharmaceuticals, Novartis Pharma, Pfizer, PharmaEssentia, Servier Pharmaceuticals LLC, Taiho Oncology, and Takeda Oncology. J.L. reports consulting and/or other fees from AbbVie, Boxer Capital, BMS, Jasper Therapeutics, Jazz Pharmaceuticals, Novartis Pharma, and Servier Pharmaceuticals. The remaining authors declare no competing financial interests."